The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women
Open accessAbstract
BACKGROUND: It is uncertain whether measurement of circulating total atherogenic lipoprotein particle cholesterol mass [non–HDL cholesterol (nonHDLc)] or particle concentration [apolipoprotein B (apo B) and LDL particle concentration (LDLp)] more accurately reflects risk of incident coronary heart disease (CHD). We evaluated CHD risk among women in whom these markers where discordant. METHODS: Among 27533 initially healthy women in the Women's Health Study (NCT00000479), using residuals from linear regression models, we compared risk among women with higher or lower observed particle concentration relative to nonHDLc (highest and lowest residual quartiles, respectively) to individuals with agreement between markers (middle quartiles) using Cox proportional hazards models. RESULTS: Although all 3 biomarkers were correlated (r ≥ 0.77), discordance occurred in up to 20.2% of women. Women with discordant high particle concentration were more likely to have metabolic syndrome (MetS) and diabetes (both P < 0.001). Over a median follow-up of 20.4 years, 1246 CHD events occurred (514725 person-years). Women with high particle concentration relative to nonHDLc had increased CHD risk: age-adjusted hazard ratio (95% CI) = 1.77 (1.56–2.00) for apo B and 1.70 (1.50–1.92) for LDLp. After adjustment for clinical risk factors including MetS, these risks attenuated to 1.22 (1.07–1.39) for apo B and 1.13 (0.99–1.29) for LDLp. Discordant low apo B or LDLp relative to nonHDLc was not associated with lower risk. CONCLUSIONS: Discordance between atherogenic particle cholesterol mass and particle concentration occurs in a sizeable proportion of apparently healthy women and should be suspected clinically among women with cardiometabolic traits. In such women, direct measurement of lipoprotein particle concentration might better inform CHD risk assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“given that apoB is a more accurate measure of the adequacy of lipid-lowering therapy than LDL-C or non-HDL-C,1,3–13,27”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, all reports since then, with one exception,2 including observational studies and randomized clinical trials,3–13 have confirmed that apoB is a more accurate marker of cardiovascular risk than LDL-C or non-HDL-C, reinforcing the validity of the evaluation by the 2019 EAS/ESC Guidelines as to the superiority of apoB.”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This study builds on prior work showing that apoB concentration is the most predictive parameter of CV risk,13,14,15”
From Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis (2022) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Self-citationTabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Lee, I.-M., Cook, N. R., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.56 · Cited by 1,137
Self-citationCook, N. R., Lee, I.-M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.1.47 · Cited by 796
Self-citationBoekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Self-citationAnderson, T. J., Grégoire, J. C., Hegele, R. A., Couture, P., Mancini, G. B. J., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C. W., Grover, S. A., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.032 · Cited by 780
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–104 of 104
Shui, X., Wen, Z., Dong, R., Chen, Z., Tang, L., Tang, W., Wu, Z., & Chen, L. (2023) · Figshare · doi:10.6084/m9.figshare.23916996
Zhang, S. K., Koyama, S., Bellomo, T. R., Haidermota, S., Hornsby, W., Honigberg, M. C., Ellinor, P. T., & Natarajan, P. (2025) · medRxiv · doi:10.64898/2025.12.11.25341921
Zhao, Y., Li, Z. L., Yu, T., Yang, Y., & Du, T. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005841
A Discordant Result of Discordance Analysis—Reply
Mortensen, M., & Nordestgaard, B. G. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.3635
Metadata
- Authors
- Lawler, P. R., Akinkuolie, A. O., Ridker, P. M., Sniderman, A. D., Buring, J. E., Glynn, R. J., Chasman, D. I., & Mora, S.
- Affiliations
- Brigham and Women's Hospital (US)
- McGill University Health Centre (CA)
- Corresponding author
- Mora, Samia
- ORCID
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-01
- Volume
- 63
- Issue
- 4
- Pages
- 870-879
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- PMC
- PMC5374022
- OpenAlex
- W2586930478
- Cited by
- 104
- References
- 26
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 7 · 2023: 15 · 2022: 14 · 2021: 16 · 2020: 6 · 2019: 10 · 2018: 13 · 2017: 8
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wisconsin Historical Society (CA047988, HL043851, HL080467, HL099355, UM1 CA182913)
- Molino Family Trust
- NIH T32 (HL007575)
- NIH LRP
- Brigham and Women's Hospital
- National Heart, Lung, and Blood Institute of the NIH under Award (R01HL117861)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- non-HDL cholesterol, apolipoprotein B, coronary heart disease risk, women, metabolic syndrome, Women's Health Study
- MeSH terms
- Apolipoproteins B, Cholesterol, Coronary Disease, Female, Humans, Middle Aged, Risk Factors, Biomarkers, Women's Health, Controlled Clinical Trials as Topic, Atherosclerosis, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
